• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies

    Novartis Invests in Credence MedSystems

    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement

    Almac Expands Global Biologics Testing Services

    GRAM Makes Major Investment in Additional Advanced Equipment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement

    GRAM Makes Major Investment in Additional Advanced Equipment

    Aphena’s $21M Cookeville Expansion Nears Completion

    PromoCell Receives EXCiPACT Certification

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Novartis Invests in Credence MedSystems

    Aphena’s $21M Cookeville Expansion Nears Completion

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies

    Almac Expands Global Biologics Testing Services

    The State of Clinical Trial Technology

    Adare Pharma Solutions Opens New Small-Scale Lab

    The Future of Clinical Trials Series: Part II
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Alcami

    Syngene

    Almac Group

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Emergent BioSolutions

    Alcami

    Cytovance Biologics

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Preclinical Outsourcing

    Strategic Intentions

    Gauging the fallout from the Covance-Sanofi pact

    Related CONTENT
    • Frontida BioPharm Launches Expansion Efforts
    • Recro Gainesville Expands Mfg. Capabilities
    • Diverse Products And Technologies Delivered
    • PPD Expands Vaccine Development Lab
    • UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Steve Snyder11.10.10

    In a year that has seen a perplexing continuation of the slowdown in customer demand for preclinical outsourcing, Covance recently announced a new strategic deal with Sanofi-Aventis. We'll explore the impact of this partnership on Covance, Sanofi, and the preclinical outsourcing industry at large.


    The Deal


    As widely reported in the financial press, Covance will become a primary provider of research services for Sanofi. It is important to note that the services provided by Covance will include clinical services and chemistry services, but this column will only focus on the impact of the deal on preclinical outsourcing. Covance will purchase Sanofi operations in France and the UK. Employees at these facilities will become Covance employees. The deal for Covance is valued as high as $2.2 billion over

    10 years.


    What Does the Deal Mean for Covance?


    Once the deal is closed, receiving between $1.2 and $2.2 billion in guaranteed revenue over the next 10 years will help Covance temper the cyclic nature of customer demand for preclinical outsourcing. The Sanofi deal follows Covance's first asset transfer deal with Lilly, which was valued at $1.6 billion for Covance. Covance has since been able to commercialize the former Lilly site in Greenfield, IN to serve other clients in addition to fulfilling its Lilly service obligations. The Sanofi deal further differentiates Covance in the industry as having the ability to close deals of this magnitude. Locking in long-term guaranteed revenue would seemingly enable more strategic decision-making and help minimize market driven reactive decisions.


    By acquiring research operations in France and the UK, Covance significantly improves its European presence. These facilities will join the existing Covance portfolio of European preclinical facilities in Harrogate, UK and Muenster, Germany. As Covance realized with the Lilly deal, one of the real benefits may be the acquisition of experienced Sanofi researchers. If managed effectively, the overall gain of research experience can only help to diversify Covance's existing scientific expertise. Like some other preclinical CROs, Covance has been adept at moving employees among its sites to address operational needs. Having additional experienced staff can only extend this flexibility. As I have stated in the past, facilities don't conduct research; people conduct research.


    What Does the Deal Mean for Sanofi?


    At a time when pharmaceutical companies are looking to cut costs, the Covance deal allows Sanofi to reduce some of its fixed overhead expenses. Transferring two research facilities and their employees to Covance helps to achieve this goal. As long as Covance performs to Sanofi's expectations, Sanofi could also benefit by reducing external service agreements and the subsequent costs associated with maintaining those relationships.


    What Are the Challenges for Covance?


    How will former Sanofi employees transition to CRO work? Working for a CRO is much different that working for a pharmaceutical company. The pace is faster and the expectations for customer service are much greater. Frankly, some individuals just aren't cut out for the CRO work environment. If Covance decides to maintain Sanofi's site management teams, these teams will need to deliver the level of research quality and service that Covance and Sanofi will expect. Again, this is easier said than done, as CRO work requires a different mindset than what is needed in pharmaceutical research operations.


    Will Covance commercialize the newly acquired Sanofi research operations? By "commercialize," I mean, will Covance look to provide services from the former Sanofi facilities for clients other than Sanofi? While Covance has proven successful in commercializing the former Lilly facility in Greenfield, IN, it has been suggested that some potential clients will not place work there due to lingering confidentiality concerns arising from Covance's partnership withLilly. Furthermore, any clients that Covance may seek to attract to the former Sanofi facilities will need to be convinced that the employee concerns that were expressed above have been addressed.


    Will Covance have too much global capacity? The preclinical outsourcing industry in 2010 is still experiencing the low customer demand that first started to decline in 2008. While it is reported that client requests for bids remain high, there has been no definitive evidence that we will see a marked improvement in demand for the immediate future. Over this timeframe, the preclinical CRO industry has cut costs through layoffs and, in some cases, reducing capacity. Despite its previous strategic deals, Covance has not been immune to these market forces. Some financial analysts have suggested that Covance may announce a cost-cutting initiative but no such news has been announced at press time. While the Sanofi sites will provide Covance with a greater presence in Europe, their management team will be challenged to balance workload across their operations. Despite best intentions and talk of teamwork, multi-site preclinical CROs can end up competing with their sister sites because individual site revenue generation is often a measure of management effectiveness. Finally, despite additional governmental scrutiny, animal liberation activities are still a significant concern for European preclinical CROs and their clients.


    Will the Sanofi facilities conduct regulated drug development activities? With the Lilly deal, Covance made a strategic decision not to conduct GLP toxicology work at the Greenfield facility, a site focused on late discovery/early development non-GLP activities. This decision enabled Covance to commercialize this facility faster, since they did not have to build the infrastructure to support GLP work. If it is determined that the Sanofi operations acquired by Covance will conduct regulated work, Covance will need to make sure that regulatory compliance is consistent with its expectations and with those of its clients. The decision could be significant in that there seems to be growing scrutiny of CRO operations by the FDA. As reported in my October 2010 Contract Pharma column, "Regulatory Shock-waves," the FDA is seeking to prevent sponsors from commenting on or editing contributor reports from CROs until the contributor report has been finalized. If this enforcement action is maintained, sponsors may become even more selective in choosing preclinical outsourcing partners; they may be inclined to work with CRO scientists who are more familiar to them. This is pure speculation but if true, it may be more difficult for any new CRO operation to be embraced by the client community.


    Is Covance's preclinical business too large to be managed effectively? There really is no standard to determine the "appropriate" size of a preclinical operation. Covance has been harmonizing multi-site preclinical operations since the mid-1990s. Their management team seemingly understands that harmonization and operational optimization is an ongoing process. Covance scientists could be challenged to balance additional harmonization efforts while maintaining an appropriate focus on ongoing client studies. Covance seems to have an appropriate management structure to direct a growing preclinical operation. Still, especially after the explosive growth in industry capacity in 2007 and 2008, some CROs have been challenged to maintain quality and acceptable service. Maintaining quality and customer service is a challenge that all CROs face on a daily basis. It is worth considering then whether this daily challenge becomes greater as a management team is tasked with additional operational and strategic responsibilities. Established work processes may not be as effective as the size of a preclinical operation expands. The problem is that a CRO may not realize that a work process is no longer effective until quality issues arise. Some clients shy away from large CROs because they are concerned that they won't receive the attention and level of customer service that they expect from an outsourcing partner. Covance will have to continue to manage this perception and proactively manage its preclinical operations.


    What Does the Deal Mean for thePreclinical Outsourcing Industry?


    If the Sanofi sites in France and the UK have preclinical capabilities, this would add capacity to a preclinical outsourcing industry that already has significant unused capacity due to low customer demand. The good news for the industry is that this would equate to lower capacity in the client community, but it appears that Covance would be the primary beneficiary of this reduction. The degree of exclusivity of the Covance-Sanofi deal will determine how much, if any, preclinical business is lost by Covance's competitors. On the other hand, the aforementioned client concerns that Covance has become too large could drive new business to small or mid-sized CROs. You can bet that Covance's competitors will jump at any opportunity to woo Covance clients, especially if any quality issues arise in the immediate future.


    Beyond the Covance-Sanofi deal, other changes in the preclinical outsourcing industry could impact the competitive landscape. It has been reported that LAB Research was recently put up for sale. Businesses are bought and sold all of the time, but such news can create uncertainty in the internal operations of a CRO and in the client community. Clients should make sure their due diligence is current and should maintain ongoing monitoring activities. Any detriment in the business of existing CROs will only benefit the competition. Along those lines, all CROs are potentially subject to operational changes due to the aforementioned stance by the FDA on contributor reports.


    The Covance-Sanofi partnership has obvious benefits for both parties. Covance will face operational challenges, just as it did with the Lilly deal, and although the preclinical outsourcing industry has experienced a long decrease in customer demand, Sanofi is a recent example of another pharmaceutical company that is diminishing its internal drug development capabilities. This trend is likely to continue as the pharmaceutical industry faces patent expirations on key drugs.


    In the end, the real significance of the Covance-Sanofi partnership may be the affirmation of a brighter future for the preclinical outsourcing industry.


    Steve Snyder is a consultant with more than 25 years of experience in preclinical toxicology as an outsourcing customer and provider. He can be contacted at info@outsource-support.com.

    Related Searches
    • Pharma
    • Preclinical
    • Toxicology
    • CRO
    Suggested For You
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Breaking New Ground: How Industry Collaboration is Transforming Clinical Research Breaking New Ground: How Industry Collaboration is Transforming Clinical Research
    Worldwide Clinical Trials Names EVP of Global BD Worldwide Clinical Trials Names EVP of Global BD
    Celerion Appoints CMO Celerion Appoints CMO
    Ancillare Appoints Asia-Pac VP Ancillare Appoints Asia-Pac VP
    Veeva Systems Expands Leadership Team Veeva Systems Expands Leadership Team
    12 Lilly 12 Lilly
    Lilly, Regen BioPharma in Drug Discovery Pact Lilly, Regen BioPharma in Drug Discovery Pact
    Lilly Licenses Halozyme’s ENHANZE platform Lilly Licenses Halozyme’s ENHANZE platform
    Lilly Halts Development of BIL Lilly Halts Development of BIL
    WuXi PharmaTech, Lilly in Strategic Development Pact WuXi PharmaTech, Lilly in Strategic Development Pact

    Related Preclinical Outsourcing

    • Drug Development | Preclinical Outsourcing | Toxicology

      Final Thoughts

      Time to say “goodbye”
      Steve Snyder, Contributing Editor 04.04.12

    • Clinical Trials | CRO News | Drug Development | Preclinical Outsourcing | Toxicology

      Outlook for 2012

      Positive signs for CROs
      Steve Snyder, Contributing Editor 03.07.12

    • Drug Development | Preclinical Outsourcing | Toxicology

      Debunking Outsourcing Myths

      The realities of preclinical drug development
      Steve Snyder 01.23.12


    • Drug Development | Preclinical Outsourcing | Toxicology

      Then and Now

      How the drug development industry has changed over the years.
      Steve Snyder 11.14.11

    • Drug Development | Inspections | Preclinical Outsourcing | Toxicology

      Preclinical FAQs

      My answers to Frequently Asked Questions
      Steve Snyder 10.11.11

    • Laboratory Testing | Preclinical Outsourcing | Toxicology

      The Ultimate Risk Factor

      The quest to control the uncontrollable
      Steve Snyder 09.07.11


    • Bioassay Development | Drug Development | Methods Development | Preclinical Outsourcing | Process Development | Toxicology

      The Best of Preclinical Outsourcing

      Excerpts from some favorite past articles
      Steve Snyder 07.13.11

    • Drug Development | Toxicology

      Got Training?

      A look at the effectiveness of employee training
      Steve Snyder, Contributing Editor 06.06.11

    • Drug Development | Preclinical Outsourcing | R&D | Toxicology

      The History of Drug Development - Part 2

      The influence of investor expectations
      Steve Snyder 04.29.11


    • Clinical Trials | Drug Development | Preclinical Outsourcing | R&D | Toxicology

      The History of Drug Development (pt. 1)

      The influence of investor expectations
      Steve Snyder 04.05.11

    • Drug Development | Preclinical Outsourcing | R&D | Toxicology

      Smart Moves For 2011

      Timely tips for sponsors
      Steve Snyder 03.07.11

    • Breaking News | Drug Discovery | Preclinical Outsourcing | R&D | Toxicology

      Investor Unrest

      What's going on at Charles River Labs?
      Steve Snyder 01.24.11


    • Clinical Trials | Drug Development | Toxicology

      Regulatory Shockwaves

      An FDA ruling stuns the industry
      Steve Snyder 10.08.10

    • Financial Reports | Industry News | Preclinical Outsourcing | Toxicology

      Black Thursday

      ...
      Steve Snyder 09.01.10

    • Preclinical Outsourcing | Toxicology

      Lessons Learned?

      Business at some preclinical CROs starts to rebound
      Steve Snyder 07.09.10

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • 500+ Sites Join Inato’s Industry Marketplace
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    Breaking News
    • Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies
    • Novartis Invests in Credence MedSystems
    • Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    • Almac Expands Global Biologics Testing Services
    • GRAM Makes Major Investment in Additional Advanced Equipment
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

      View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    PepsiCo and Beyond Meat Partner to Develop Plant-Based Protein
    New Study on Sage Extract Formula Suggests Memory Enhancement
    Omega-3s Evidenced to Reduce Low-Grade Inflammation in Elderly Men
    Coatings World

    Latest Breaking News From Coatings World

    Mississippi Lime Company Announces New Director of Safety
    IFS Coatings Launches IFS Puroplaz PE20 Texture
    Keyland Polymer UV Powder, LLC Launches UVMax Defender
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Spectrum Solutions Collaborates with UCLA School of Dentistry
    Kwivik Therapeutics, EirMed Partner to Accelerate Product Commercialization
    Europe Marks its First Successful Remote Robotic-Assisted Coronary Angioplasty
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies
    Novartis Invests in Credence MedSystems
    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty to Shut Down Manufacturing Site in Cologne, Germany
    L’Occitane Files for Bankruptcy in U.S.
    Bésame Cosmetics Collaborates with Disney on Mary Poppins Collection
    Happi

    Latest Breaking News From Happi

    HI Beach Installs Reef-friendly Sunscreen Dispenser
    RB Partners with Airbnb
    L'Occitane US Files for Bankruptcy
    Ink World

    Latest Breaking News From Ink World

    Epson Partner Creates Label Applicators for Pharmaceutical Products
    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Georgia-Pacific Acquires 3rd HP PageWide Corrugated Press to Expand Hummingbird Digital Printing
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex acquires MDV Group
    Fix-A-Form eyes global expansion
    McCracken Label installs Fujifilm water-wash plate system
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Nice-Pak Receives EPA Approval for Disinfecting Wipes
    Rockline to Invest $18 Million in Arkansas
    Essity’s Sales Negatively Impacted by Covid-19 Pandemic
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ChoiceSpine's Tiger Shark Cervical Spacer Earns Additional 510(k)
    FDA Green Lights Inspired Spine's Trident SI Joint Screw System
    FDA Clears Method to Extract Bone Measurements From X-Rays
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Osram Sees Jump in Profits in Preliminary 2020 Report
    LG Display Reports 4Q 2020 Results
    Xerox Releases 4Q, Full Year Results

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login